Literature DB >> 16884307

Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors.

Robert M Immormino1, Yanlong Kang, Gabriela Chiosis, Daniel T Gewirth.   

Abstract

Hsp90 chaperones play a critical role in modulating the activity of many cell signaling proteins and are an attractive target for anti-cancer therapeutics. We report here the structures of the water soluble 8-aryl-sulfanyl adenine class Hsp90 inhibitors, 1 (PU-H71) and 2 (PU-H64), in complex with the N-terminal domain of human Hsp90alpha. The conformation of 1 when bound to Hsp90 differs from previously reported 8-aryl adenine Hsp90 inhibitors including 3 (PU24FCl). While the binding mode for 3 places the 2'-halide of the 8-aryl group on top of the adenine ring, for 1 and 2, we show that the 2'-halide is rotated approximately 180 degrees away. This difference explains the opposing trends in Hsp90 inhibitory activity for the 2'-halo derivatives of the 3',4',5'-trimethoxy series where Cl > Br > I compared to the 4',5'-methylenedioxy series where I > Br > Cl. We also present quantum chemical calculations of 2 and its analogues that illuminate their basis for Hsp90 inhibition. The calculated conformation of 2 agreed well with the crystallographically observed conformations of 1 and 2. The predictive nature of the calculations has allowed the exploration of additional derivatives based on the 8-aryl adenine scaffold.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884307     DOI: 10.1021/jm060297x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  40 in total

1.  Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.

Authors:  Simona Tomaselli; Massimiliano Meli; Janet Plescia; Lucia Zetta; Dario C Altieri; Giorgio Colombo; Laura Ragona
Journal:  Chem Biol Drug Des       Date:  2010-11       Impact factor: 2.817

2.  Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.

Authors:  Pallav D Patel; Pengrong Yan; Paul M Seidler; Hardik J Patel; Weilin Sun; Chenghua Yang; Nanette S Que; Tony Taldone; Paola Finotti; Ralph A Stephani; Daniel T Gewirth; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2013-09-01       Impact factor: 15.040

Review 3.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

4.  Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Authors:  Hardik J Patel; Pallav D Patel; Stefan O Ochiana; Pengrong Yan; Weilin Sun; Maulik R Patel; Smit K Shah; Elisa Tramentozzi; James Brooks; Alexander Bolaender; Liza Shrestha; Ralph Stephani; Paola Finotti; Cynthia Leifer; Zihai Li; Daniel T Gewirth; Tony Taldone; Gabriela Chiosis
Journal:  J Med Chem       Date:  2015-04-22       Impact factor: 7.446

Review 5.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

6.  First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.

Authors:  Giovanna Speranza; Larry Anderson; Alice P Chen; Khanh Do; Michelle Eugeni; Marcie Weil; Larry Rubinstein; Eva Majerova; Jerry Collins; Yvonne Horneffer; Lamin Juwara; Jennifer Zlott; Rachel Bishop; Barbara A Conley; Howard Streicher; Joseph Tomaszewski; James H Doroshow; Shivaani Kummar
Journal:  Invest New Drugs       Date:  2017-08-12       Impact factor: 3.850

7.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Authors:  Jimmy Lee; Liang Leo Zhang; Wenjun Wu; Hui Guo; Yan Li; Madina Sukhanova; Girish Venkataraman; Shengjian Huang; Hui Zhang; Mir Alikhan; Pin Lu; Ailin Guo; Natalie Galanina; Jorge Andrade; Michael L Wang; Y Lynn Wang
Journal:  Blood Adv       Date:  2018-08-28

8.  Systematic identification of the HSP90 candidate regulated proteome.

Authors:  Zhixiang Wu; Amin Moghaddas Gholami; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2012-02-14       Impact factor: 5.911

9.  Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay.

Authors:  Thota Ganesh; Pahk Thepchatri; Lian Li; Yuhong Du; Haian Fu; James P Snyder; Aiming Sun
Journal:  Bioorg Med Chem Lett       Date:  2008-08-14       Impact factor: 2.823

10.  Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer.

Authors:  Giulia Morra; Gennady Verkhivker; Giorgio Colombo
Journal:  PLoS Comput Biol       Date:  2009-03-20       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.